These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1230 related items for PubMed ID: 8614504

  • 41. Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans.
    Jhoo JH, Kim KW, Lee DY, Lee KU, Lee JH, Kim SY, Youn JY, Youn JC, Woo JI.
    J Neurol Sci; 2001 Feb 15; 184(1):21-5. PubMed ID: 11231028
    [Abstract] [Full Text] [Related]

  • 42. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset.
    Hirono N, Hashimoto M, Yasuda M, Ishii K, Sakamoto S, Kazui H, Mori E.
    Neurology; 2002 Mar 12; 58(5):743-50. PubMed ID: 11889238
    [Abstract] [Full Text] [Related]

  • 43. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease.
    Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ.
    Psychol Aging; 1999 Jun 12; 14(2):295-303. PubMed ID: 10403716
    [Abstract] [Full Text] [Related]

  • 44. Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele.
    Wishart HA, Saykin AJ, Rabin LA, Santulli RB, Flashman LA, Guerin SJ, Mamourian AC, Belloni DR, Rhodes CH, McAllister TW.
    Am J Psychiatry; 2006 Sep 12; 163(9):1603-10. PubMed ID: 16946187
    [Abstract] [Full Text] [Related]

  • 45. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.
    Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO.
    BMC Neurol; 2008 Apr 16; 8():9. PubMed ID: 18416843
    [Abstract] [Full Text] [Related]

  • 46. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.
    Laws SM, Hone E, Gandy S, Martins RN.
    J Neurochem; 2003 Mar 16; 84(6):1215-36. PubMed ID: 12614323
    [Abstract] [Full Text] [Related]

  • 47. Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early- and late-onset sporadic Alzheimer's disease.
    Panza F, Solfrizzi V, Torres F, Mastroianni F, Colacicco AM, Basile AM, Capurso C, D'Introno A, Del Parigi A, Capurso A.
    Neurosci Lett; 2000 Oct 06; 292(2):79-82. PubMed ID: 10998553
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.
    Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Beiser A, Wolf PA.
    Neurology; 1996 Mar 06; 46(3):673-7. PubMed ID: 8618665
    [Abstract] [Full Text] [Related]

  • 52. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C, Wallin ÅK.
    Alzheimers Res Ther; 2017 Aug 31; 9(1):70. PubMed ID: 28859660
    [Abstract] [Full Text] [Related]

  • 53. Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
    Smirnov DS, Galasko D, Hiniker A, Edland SD, Salmon DP.
    Neurology; 2021 May 04; 96(18):e2272-e2283. PubMed ID: 33722993
    [Abstract] [Full Text] [Related]

  • 54. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset.
    Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C.
    Eur J Neurol; 2006 Feb 04; 13(2):176-82. PubMed ID: 16490049
    [Abstract] [Full Text] [Related]

  • 55. APOE ε4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death.
    Yu L, Boyle P, Schneider JA, Segawa E, Wilson RS, Leurgans S, Bennett DA.
    Psychol Aging; 2013 Dec 04; 28(4):1015-23. PubMed ID: 23647000
    [Abstract] [Full Text] [Related]

  • 56. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease.
    Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD.
    Ann Neurol; 1995 Oct 04; 38(4):678-80. PubMed ID: 7574468
    [Abstract] [Full Text] [Related]

  • 57. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
    Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.
    Int J Geriatr Psychiatry; 1998 Nov 04; 13(11):767-74. PubMed ID: 9850873
    [Abstract] [Full Text] [Related]

  • 58. Genetic risk factors in Japanese Alzheimer's disease patients: alpha1-ACT, VLDLR, and ApoE.
    Yamanaka H, Kamimura K, Tanahashi H, Takahashi K, Asada T, Tabira T.
    Neurobiol Aging; 1998 Nov 04; 19(1 Suppl):S43-6. PubMed ID: 9562467
    [Abstract] [Full Text] [Related]

  • 59. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
    Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S.
    J Neurol Neurosurg Psychiatry; 1996 Dec 04; 61(6):580-3. PubMed ID: 8971103
    [Abstract] [Full Text] [Related]

  • 60. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.
    Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL.
    Neurology; 2003 Jan 28; 60(2):246-52. PubMed ID: 12552039
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.